Robert J. Schotzinger

3.0k total citations · 1 hit paper
52 papers, 2.4k citations indexed

About

Robert J. Schotzinger is a scholar working on Infectious Diseases, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert J. Schotzinger has authored 52 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 26 papers in Epidemiology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert J. Schotzinger's work include Antifungal resistance and susceptibility (32 papers), Fungal Infections and Studies (21 papers) and Prostate Cancer Treatment and Research (10 papers). Robert J. Schotzinger is often cited by papers focused on Antifungal resistance and susceptibility (32 papers), Fungal Infections and Studies (21 papers) and Prostate Cancer Treatment and Research (10 papers). Robert J. Schotzinger collaborates with scholars based in United States, United Kingdom and Switzerland. Robert J. Schotzinger's co-authors include Story C. Landis, Edward P. Garvey, William J. Hoekstra, Christopher M. Yates, William R. Moore, Thorsten P. Degenhardt, Nathan P. Wiederhold, W. HOEKSTRA, Galina I. Lepesheva and Tatiana Y. Hargrove and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Neuron.

In The Last Decade

Robert J. Schotzinger

52 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis

2017 317 citations Tatiana Y. Hargrove, Laura Friggeri et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Robert J. Schotzinger

Since Specialization

Citations

This map shows the geographic impact of Robert J. Schotzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Schotzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Schotzinger more than expected).

Fields of papers citing papers by Robert J. Schotzinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Schotzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Schotzinger. The network helps show where Robert J. Schotzinger may publish in the future.

Co-authorship network of co-authors of Robert J. Schotzinger

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Schotzinger. A scholar is included among the top collaborators of Robert J. Schotzinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Schotzinger. Robert J. Schotzinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis 2020 ·Clinical Infectious Diseases ·Stephen Brand, Jack D. Sobel, Paul Nyirjesy, Mahmoud A. Ghannoum, Robert J. Schotzinger, Thorsten P. Degenhardt	45
2	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis 2018 ·American Journal of Obstetrics and Gynecology ·Stephen Brand, Thorsten P. Degenhardt, (unknown), Jack D. Sobel, Paul Nyirjesy, Robert J. Schotzinger, Amir Tavakkol	59
3	VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice 2018 ·Journal of Antimicrobial Chemotherapy ·Timothy J. Break, Jigar V. Desai, Kelley R. Healey, Mukil Natarajan, Elise M. N. Ferré, Christina Henderson, Adrian M. Zelazny, Ulrich Siebenlist, Christopher M. Yates, Oren J. Cohen, Robert J. Schotzinger, David S. Perlin, Edward P. Garvey, Michail S. Lionakis	26
4	Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus 2017 ·Journal of Antimicrobial Chemotherapy ·Nathan P. Wiederhold, Hoja Patterson, (unknown), Christopher M. Yates, Robert J. Schotzinger, Edward P. Garvey	56
5	Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors 2017 ·Bioorganic & Medicinal Chemistry Letters ·Christopher M. Yates, Edward P. Garvey, Sammy R. Shaver, Robert J. Schotzinger, William J. Hoekstra	71
6	Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis 2017 ·American Journal of Obstetrics and Gynecology ·Jack D. Sobel, Stephen Brand, Thorsten P. Degenhardt, (unknown), Paul Nyirjesy, Robert J. Schotzinger, Amir Tavakkol	5
7	Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis breakdown → 2017 ·Journal of Biological Chemistry ·Tatiana Y. Hargrove, Laura Friggeri, Z. Wawrzak, Aidong Qi, William J. Hoekstra, Robert J. Schotzinger, John D. York, F. Peter Guengerich, Galina I. Lepesheva	317
8	Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs 2017 ·Antimicrobial Agents and Chemotherapy ·Lisa F. Shubitz, (unknown), Hien T. Trinh, William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey	16
9	Activity of VT-1129 againstCryptococcus neoformansclinical isolates with high fluconazole MICs 2016 ·Medical Mycology ·Kirsten Nielsen, (unknown), Kyle D. Smith, David B. Meya, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, David R. Boulware	23
10	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC. 2015 ·Journal of Clinical Oncology ·Johann S. de Bono, Carmel Pezaro, Silke Gillessen, Neal D. Shore, Luke T. Nordquist, Eleni Efstathiou, John C. Araujo, William R. Berry, Glenn Liu, Nicholas J. Vogelzang, Aurelius Omlin, Robert J. Schotzinger, Joel R. Eisner, William R. Moore	9
11	Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models 2015 ·Antimicrobial Agents and Chemotherapy ·Lisa F. Shubitz, Hien T. Trinh, John N. Galgiani, (unknown), Annette W. Fothergill, Nathan P. Wiederhold, Bridget M. Barker, (unknown), (unknown), William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey	41
12	The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme 2014 ·Antimicrobial Agents and Chemotherapy ·Andrew G. S. Warrilow, Claire M. Hull, Josie E. Parker, Edward P. Garvey, W. HOEKSTRA, William R. Moore, Robert J. Schotzinger, Diane Kelly, Steven L. Kelly	134
13	Design and optimization of highly-selective fungal CYP51 inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·William J. Hoekstra, Edward P. Garvey, William R. Moore, (unknown), Christopher M. Yates, Robert J. Schotzinger	152
14	Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Joel R. Eisner, William R. Moore, Robert J. Schotzinger, William J. Hoekstra	45
15	VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC). 2012 ·Journal of Clinical Oncology ·Joel R. Eisner, David H. Abbott, Ian M. Bird, (unknown), William R. Moore, Robert J. Schotzinger	17
16	Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy 2007 ·American Journal of Nephrology ·Mark E. Williams, W. Kline Bolton, Raja G. Khalifah, Thorsten P. Degenhardt, Robert J. Schotzinger, Janet B. McGill	202
17	Target determination of neurotransmitter phenotype in sympathetic neurons 1994 ·Journal of Neurobiology ·Robert J. Schotzinger, (unknown), Story C. Landis	94
18	Acquisition of cholinergic and peptidergic properties by sympathetic innervation of rat sweat glands requires interaction with normal target 1990 ·Neuron ·Robert J. Schotzinger, Story C. Landis	107
19	Postnatal development of autonomic and sensory innervation of thoracic hairy skin in the rat 1990 ·Cell and Tissue Research ·Robert J. Schotzinger, Story C. Landis	51
20	Cholinergic phenotype developed by noradrenergic sympathetic neurons after innervation of a novel cholinergic target in vivo 1988 ·Nature ·Robert J. Schotzinger, Story C. Landis	183

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact